BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001. [PMID: 11041404 DOI: 10.1016/s0140-6736(00)02694-5] [Cited by in Crossref: 669] [Cited by in F6Publishing: 110] [Article Influence: 31.9] [Reference Citation Analysis]
Number Citing Articles
1 Smith TE, Steven A, Bagert BA. Gadolinium Deposition in Neurology Clinical Practice. Ochsner J 2019;19:17-25. [PMID: 30983897 DOI: 10.31486/toj.18.0111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, Dame MK, Varani J. Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 2011;144:621-35. [PMID: 21484406 DOI: 10.1007/s12011-011-9041-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
3 Kirchin MA, Lorusso V, Pirovano G. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 2015;88:20140526. [PMID: 25651409 DOI: 10.1259/bjr.20140526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
4 Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010;31:440-6. [PMID: 20099361 DOI: 10.1002/jmri.22024] [Cited by in Crossref: 84] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
5 Leyba K, Wagner B. Gadolinium-based contrast agents: why nephrologists need to be concerned. Curr Opin Nephrol Hypertens 2019;28:154-62. [PMID: 30531473 DOI: 10.1097/MNH.0000000000000475] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
6 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
7 Leiner T, Herborn CU, Goyen M. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 2007;17:1921-3. [PMID: 17458550 DOI: 10.1007/s00330-007-0663-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
8 Kuo DP, Lu CF, Liou M, Chen YC, Chung HW, Chen CY. Differentiation of the Infarct Core from Ischemic Penumbra within the First 4.5 Hours, Using Diffusion Tensor Imaging-Derived Metrics: A Rat Model. Korean J Radiol 2017;18:269-78. [PMID: 28246507 DOI: 10.3348/kjr.2017.18.2.269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
10 Sharma J, Mongia A, Schoenaman M, Chang S, D'Angelo A, Rao M. Nephrogenic fibrosing dermatopathy, cardiac calcification and pulmonary hypertension in an adolescent on chronic hemodialysis. Indian J Nephrol 2008;18:70-3. [PMID: 20142906 DOI: 10.4103/0971-4065.42340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Chang P, Saddleton E, Laumann AE, Schmitz B, West DP, Belknap SM, Parthasarathy S, Edwards BJ, McKoy JM, Miller FH. Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function. Acad Radiol 2012;19:1181-5. [PMID: 22831822 DOI: 10.1016/j.acra.2012.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Paniagua RT, Fiorentino DF, Chung L, Robinson WH. Tyrosine kinases in inflammatory dermatologic disease. J Am Acad Dermatol 2011;65:389-403. [PMID: 20584561 DOI: 10.1016/j.jaad.2010.04.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
14 Steen H, Schwenger V. Good MRI images: to Gad or not to Gad? Pediatr Nephrol 2007;22:1239-42. [PMID: 17574478 DOI: 10.1007/s00467-007-0509-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
15 Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 2010;64:1274-80. [PMID: 20648683 DOI: 10.1002/mrm.22553] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
16 Michaely HJ, Aschauer M, Deutschmann H, Bongartz G, Gutberlet M, Woitek R, Ertl-Wagner B, Kucharczyk W, Hammerstingl R, De Cobelli F, Rosenberg M, Balzer T, Endrikat J. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Invest Radiol 2017;52:55-60. [PMID: 27529464 DOI: 10.1097/RLI.0000000000000307] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
17 Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol. 2014;44:173-180. [PMID: 24057195 DOI: 10.1007/s00247-013-2795-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
18 Endrikat J, Dohanish S, Schleyer N, Schwenke S, Agarwal S, Balzer T. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. Invest Radiol 2018;53:541-50. [PMID: 29547493 DOI: 10.1097/RLI.0000000000000462] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 11.5] [Reference Citation Analysis]
19 Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015;50:416-22. [PMID: 25756684 DOI: 10.1097/RLI.0000000000000145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 7.8] [Reference Citation Analysis]
20 Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World J Gastroenterol. 2016;22:89-102. [PMID: 26755862 DOI: 10.3748/wjg.v22.i1.89] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Perone PA, Weber SL, DaSilva M, Paruchuri T, Bhagavathula N, Aslam MN, Dame MK, Johnson KJ, Swartz RD, Varani J. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 2010;45:42-8. [PMID: 19996758 DOI: 10.1097/RLI.0b013e3181bf95eb] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73. [PMID: 18545998 DOI: 10.1007/s00330-008-0977-y] [Cited by in Crossref: 153] [Cited by in F6Publishing: 127] [Article Influence: 11.8] [Reference Citation Analysis]
23 Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18. [PMID: 19404939 DOI: 10.1002/art.24471] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
24 Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189:318-27. [PMID: 22649203 DOI: 10.4049/jimmunol.1103099] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
25 Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489-496; quiz 602-603. [PMID: 17943276 DOI: 10.1007/s00247-007-0633-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
26 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
27 Hanna RF, Finkelstone LA, Chow DS, Miloushev VZ, Escudero MR, Lagana SM, Prince MR. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014;2014:679605. [PMID: 24778878 DOI: 10.1155/2014/679605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Karcaaltincaba M, Oguz B, Haliloglu M. Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 2009;39 Suppl 3:382-4. [PMID: 19440757 DOI: 10.1007/s00247-009-1236-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Drel VR, Tan C, Barnes JL, Gorin Y, Lee DY, Wagner B. Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis. FASEB J 2016;30:3026-38. [PMID: 27221979 DOI: 10.1096/fj.201500188R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
30 Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol 2015;30:515-21. [PMID: 25212105 DOI: 10.1007/s00467-014-2953-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
31 Mier W, Mier D. Advantages in functional imaging of the brain. Front Hum Neurosci 2015;9:249. [PMID: 26042013 DOI: 10.3389/fnhum.2015.00249] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
32 Noda SM, Oztek MA, Stanescu AL, Maloney E, Shaw DWW, Iyer RS. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families. Pediatr Radiol 2021. [PMID: 33978802 DOI: 10.1007/s00247-021-04973-5] [Reference Citation Analysis]
33 Wang J, Salzillo T, Jiang Y, Mackeyev Y, David Fuller C, Chung C, Choi S, Hughes N, Ding Y, Yang J, Vedam S, Krishnan S. Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac. Radiother Oncol 2021;161:55-64. [PMID: 34089753 DOI: 10.1016/j.radonc.2021.05.023] [Reference Citation Analysis]
34 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
35 Cowell GW, Reid AW, Roditi GH. Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. Insights Imaging 2012;3:495-504. [PMID: 22865510 DOI: 10.1007/s13244-012-0188-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Haneder S, Gutfleisch A, Meier C, Brade J, Hannak D, Schoenberg SO, Becker CR, Michaely HJ. Evaluation of a handheld creatinine measurement device for real-time determination of serum creatinine in radiology departments. World J Radiol 2012;4:328-34. [PMID: 22900135 DOI: 10.4329/wjr.v4.i7.328] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
37 Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017;53:306-36. [PMID: 28712039 DOI: 10.1007/s12016-017-8625-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
38 Elmholdt TR, Olesen AB, Jørgensen B, Kvist S, Skov L, Thomsen HS, Marckmann P, Pedersen M. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013;8:e82037. [PMID: 24349178 DOI: 10.1371/journal.pone.0082037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
39 Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6:553-558. [PMID: 26253982 DOI: 10.1007/s13244-015-0420-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 79] [Article Influence: 18.5] [Reference Citation Analysis]
40 Pao VY, Chang S, Shoback DM, Bikle DD. Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. J Bone Miner Res 2009;24:1135-9. [PMID: 19113910 DOI: 10.1359/jbmr.081261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
41 Aggarwal A, Froehlich AA, Essah P, Brinster N, High WA, Downs RW. Complications of nephrogenic systemic fibrosis following repeated exposure to gadolinium in a man with hypothyroidism: a case report. J Med Case Rep 2011;5:566. [PMID: 22152227 DOI: 10.1186/1752-1947-5-566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Unruh C, Van Bavel N, Anikovskiy M, Prenner EJ. Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks. Molecules 2020;25:E5762. [PMID: 33297578 DOI: 10.3390/molecules25235762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33. [PMID: 20959327 DOI: 10.1136/ard.2010.134858] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
44 George SJ, Webb SM, Abraham JL, Cramer SP. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010;163:1077-81. [PMID: 20560953 DOI: 10.1111/j.1365-2133.2010.09918.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
45 Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med 2012;27:1697-703. [PMID: 22692632 DOI: 10.1007/s11606-012-2098-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
46 Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med. 2015;4:2. [PMID: 25852818 DOI: 10.1186/s40169-015-0047-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 13.8] [Reference Citation Analysis]
47 Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;26:1190-7. [PMID: 17969161 DOI: 10.1002/jmri.21135] [Cited by in Crossref: 186] [Cited by in F6Publishing: 140] [Article Influence: 14.3] [Reference Citation Analysis]
48 Avedano S, Botta M, Haigh JS, Longo DL, Woods M. Coupling fast water exchange to slow molecular tumbling in Gd3+ chelates: why faster is not always better. Inorg Chem 2013;52:8436-50. [PMID: 23841587 DOI: 10.1021/ic400308a] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
49 Cui C, Wang S, Lu M, Duan X, Wang H, Jia L, Tang Y, Sirajuddin A, Prasad SK, Kellman P, Arai AE, Zhao S. Detection of Recent Myocardial Infarction Using Native T1 Mapping in a Swine Model: A Validation Study. Sci Rep 2018;8:7391. [PMID: 29743511 DOI: 10.1038/s41598-018-25693-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
50 Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23. [PMID: 20570839 DOI: 10.1136/ard.2009.127761] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
51 Caufield JH, Zhou Y, Garlid AO, Setty SP, Liem DA, Cao Q, Lee JM, Murali S, Spendlove S, Wang W, Zhang L, Sun Y, Bui A, Hermjakob H, Watson KE, Ping P. A reference set of curated biomedical data and metadata from clinical case reports. Sci Data 2018;5:180258. [PMID: 30457569 DOI: 10.1038/sdata.2018.258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
52 Mallio CA, Quattrocchi CC, Rovira À, Parizel PM. Gadolinium Deposition Safety: Seeking the Patient's Perspective. AJNR Am J Neuroradiol 2020;41:944-6. [PMID: 32381539 DOI: 10.3174/ajnr.A6586] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Malikova H. Nephrogenic systemic fibrosis: the end of the story? Quant Imaging Med Surg 2019;9:1470-4. [PMID: 31559176 DOI: 10.21037/qims.2019.07.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. Ann Rheum Dis 2015;74:2062-9. [PMID: 24914072 DOI: 10.1136/annrheumdis-2013-204900] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
55 Morgan ND, Hummers LK. Scleroderma Mimickers. Curr Treatm Opt Rheumatol 2016;2:69-84. [PMID: 28473954 DOI: 10.1007/s40674-016-0038-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
56 Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep 2012;14:39-46. [PMID: 22131103 DOI: 10.1007/s11926-011-0220-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
57 Twombley K, Baum M, Gattineni J. Accidental and iatrogenic causes of acute kidney injury. Curr Opin Pediatr 2011;23:208-14. [PMID: 21293274 DOI: 10.1097/MOP.0b013e328343cd16] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
58 Crane JK. Metal Nanoparticles in Infection and Immunity. Immunol Invest 2020;49:794-807. [PMID: 32524902 DOI: 10.1080/08820139.2020.1776724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
59 Jain SM, Wesson S, Hassanein A, Canova E, Hoy M, Fennell RS, Dharnidharka VR. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2004;19:467-70. [PMID: 14872332 DOI: 10.1007/s00467-003-1380-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
60 Hoggard N, Roditi GH. T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition? Br J Radiol 2017;90:20160590. [PMID: 27653560 DOI: 10.1259/bjr.20160590] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
61 Weiss PF, Xiao R, Biko DM, Johnson AM, Chauvin NA. Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary? Arthritis Rheumatol 2015;67:2250-6. [PMID: 25892309 DOI: 10.1002/art.39159] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
62 Saxena SK, Sharma M, Patel M, Oreopoulos D. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol 2008;40:715-24. [PMID: 18418727 DOI: 10.1007/s11255-008-9361-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
63 Walker JP, Nosova E, Sigovan M, Rapp J, Grenon MS, Owens CD, Gasper WJ, Saloner DA. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Ann Vasc Surg 2015;29:63-8. [PMID: 25269682 DOI: 10.1016/j.avsg.2014.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
64 Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82-8. [PMID: 22833806 DOI: 10.1093/ckj/sfr172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
65 Boujan T, Neuberger U, Pfaff J, Nagel S, Herweh C, Bendszus M, Möhlenbruch MA. Value of Contrast-Enhanced MRA versus Time-of-Flight MRA in Acute Ischemic Stroke MRI. AJNR Am J Neuroradiol 2018;39:1710-6. [PMID: 30115678 DOI: 10.3174/ajnr.A5771] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 6.7] [Reference Citation Analysis]
66 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
67 Lyapustina T, Goldfine C, Rhyee S, Babu KM, Griswold MK. Evaluating the Patient with Reported Gadolinium-Associated Illness. J Med Toxicol 2019;15:36-44. [PMID: 30499040 DOI: 10.1007/s13181-018-0689-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
69 Kawada H, Goshima S, Sakurai K, Noda Y, Kajita K, Tanahashi Y, Kawai N, Ishida N, Shimabukuro K, Doi K, Matsuo M. Utility of Noncontrast Magnetic Resonance Angiography for Aneurysm Follow-Up and Detection of Endoleaks after Endovascular Aortic Repair. Korean J Radiol 2021;22:513-24. [PMID: 33543842 DOI: 10.3348/kjr.2020.0001] [Reference Citation Analysis]
70 Samtleben W. [Nephrogenic systemic fibrosis]. Radiologe 2007;47:778-84. [PMID: 17717643 DOI: 10.1007/s00117-007-1545-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
71 Pedrosa I, Rafatzand K, Robson P, Wagner AA, Atkins MB, Rofsky NM, Alsop DC. Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol 2012;22:484-92. [PMID: 21877173 DOI: 10.1007/s00330-011-2250-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
72 Siedek F, Muehe AM, Theruvath AJ, Avedian R, Pribnow A, Spunt SL, Liang T, Farrell C, Daldrup-Link HE. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. Eur Radiol 2020;30:1790-803. [PMID: 31844962 DOI: 10.1007/s00330-019-06569-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
73 Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Fisher GJ, Johnson KJ, Swartz R, Varani J. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 2009;44:433-9. [PMID: 19561517 DOI: 10.1097/RLI.0b013e3181a4d7e9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
74 Pullicino R, Radon M, Biswas S, Bhojak M, Das K. A Review of the Current Evidence on Gadolinium Deposition in the Brain. Clin Neuroradiol 2018;28:159-69. [PMID: 29523896 DOI: 10.1007/s00062-018-0678-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
75 Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238-249. [PMID: 16461069 DOI: 10.1016/j.semarthrit.2005.08.002] [Cited by in Crossref: 194] [Cited by in F6Publishing: 155] [Article Influence: 12.9] [Reference Citation Analysis]
76 Richards PJ, McCall IW, Day C, Belcher J, Maffulli N. Longitudinal microvascularity in Achilles tendinopathy (power Doppler ultrasound, magnetic resonance imaging time-intensity curves and the Victorian Institute of Sport Assessment-Achilles questionnaire): a pilot study. Skeletal Radiol 2010;39:509-21. [PMID: 19711073 DOI: 10.1007/s00256-009-0772-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
77 Christie A, Roditi G. Vascular imaging: the evolving role of the multidisciplinary team meeting in peripheral vascular disease. Semin Intervent Radiol 2014;31:320-9. [PMID: 25435657 DOI: 10.1055/s-0034-1393968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Nouh MR, El-Shazly MA. Radiographic and magnetic resonances contrast agents: Essentials and tips for safe practices. World J Radiol 2017;9:339-49. [PMID: 29098067 DOI: 10.4329/wjr.v9.i9.339] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
79 McCray CJ, Mayes MD. Update on systemic sclerosis. Curr Allergy Asthma Rep 2015;15:25. [PMID: 26139334 DOI: 10.1007/s11882-015-0526-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
80 Sahni VA, Silverman SG. Imaging management of incidentally detected small renal masses. Semin Intervent Radiol 2014;31:9-19. [PMID: 24596435 DOI: 10.1055/s-0033-1363838] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
81 Elmholdt TR, Jørgensen B, Ramsing M, Pedersen M, Olesen AB. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010;3:285-7. [PMID: 28657062 DOI: 10.1093/ndtplus/sfq028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
82 Nörenberg D, Schmidt F, Schinke K, Frenzel T, Pietsch H, Giese A, Ertl-Wagner B, Levin J. Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS One 2020;15:e0231495. [PMID: 32324769 DOI: 10.1371/journal.pone.0231495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
83 Li C, Hu A, Haacke M, Wang J, Zhao J, Zhou D. Direct portal vein thrombosis visualization with t2*--weighted magnetic resonance imaging. Int J Med Sci 2013;10:1570-4. [PMID: 24046533 DOI: 10.7150/ijms.6681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
84 Le Fur M, Caravan P. The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. Metallomics 2019;11:240-54. [PMID: 30516229 DOI: 10.1039/c8mt00302e] [Cited by in Crossref: 55] [Cited by in F6Publishing: 13] [Article Influence: 55.0] [Reference Citation Analysis]
85 Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010;83:590-5. [PMID: 20413447 DOI: 10.1259/bjr/17689538] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
86 Huynh K, Baghdanian AH, Baghdanian AA, Sun DS, Kolli KP, Zagoria RJ. Updated guidelines for intravenous contrast use for CT and MRI. Emerg Radiol 2020;27:115-26. [PMID: 31925592 DOI: 10.1007/s10140-020-01751-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
87 Riser BL, Bhagavathula N, Perone P, Garchow K, Xu Y, Fisher GJ, Najmabadi F, Attili D, Varani J. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal 2012;6:97-105. [PMID: 22648571 DOI: 10.1007/s12079-012-0164-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
88 Matter CM, Stuber M, Nahrendorf M. Imaging of the unstable plaque: how far have we got? Eur Heart J 2009;30:2566-74. [PMID: 19833636 DOI: 10.1093/eurheartj/ehp419] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
89 Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
90 Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-75. [PMID: 18385397 DOI: 10.2215/CJN.00100108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
91 Dambreville S, Chapman AB, Torres VE, King BF, Wallin AK, Frakes DH, Yoganathan AP, Wijayawardana SR, Easley K, Bae KT, Brummer ME; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects. Magn Reson Med 2010;63:940-50. [PMID: 20373395 DOI: 10.1002/mrm.22278] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
92 Kuo DP, Kuo PC, Chen YC, Kao YJ, Lee CY, Chung HW, Chen CY. Machine learning-based segmentation of ischemic penumbra by using diffusion tensor metrics in a rat model. J Biomed Sci 2020;27:80. [PMID: 32664906 DOI: 10.1186/s12929-020-00672-9] [Reference Citation Analysis]
93 Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008;180:830-5; discussion 835. [PMID: 18635232 DOI: 10.1016/j.juro.2008.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
94 Zelasko S, Hollingshead M, Castillo M, Bouldin TW. CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis. AJNR Am J Neuroradiol 2008;29:1880-2. [PMID: 18854445 DOI: 10.3174/ajnr.A1225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Ranga A, Agarwal Y, Garg KJ. Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function. Indian J Radiol Imaging 2017;27:141-7. [PMID: 28744073 DOI: 10.4103/0971-3026.209212] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 29.0] [Reference Citation Analysis]
96 Thomsen HS, Morcos SK, Almén T, Bellin MF, Bertolotto M, Bongartz G, Clement O, Leander P, Heinz-Peer G, Reimer P. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307-318. [PMID: 22865271 DOI: 10.1007/s00330-012-2597-9] [Cited by in Crossref: 305] [Cited by in F6Publishing: 217] [Article Influence: 33.9] [Reference Citation Analysis]
97 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
98 Lange S, Mędrzycka-Dąbrowska W, Zorena K, Dąbrowski S, Ślęzak D, Malecka-Dubiela A, Rutkowski P. Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review. Int J Environ Res Public Health 2021;18:3000. [PMID: 33804005 DOI: 10.3390/ijerph18063000] [Reference Citation Analysis]
99 Wallnöfer EA, Thurner GC, Kremser C, Talasz H, Stollenwerk MM, Helbok A, Klammsteiner N, Albrecht-Schgoer K, Dietrich H, Jaschke W, Debbage P. Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. Histochem Cell Biol 2021;155:19-73. [PMID: 33040183 DOI: 10.1007/s00418-020-01919-0] [Reference Citation Analysis]
100 Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? MAGMA 2007;20:57-62. [PMID: 17436028 DOI: 10.1007/s10334-007-0071-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
101 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
102 Yantasee W, Fryxell GE, Porter GA, Pattamakomsan K, Sukwarotwat V, Chouyyok W, Koonsiripaiboon V, Xu J, Raymond KN. Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis. Nanomedicine 2010;6:1-8. [PMID: 19447204 DOI: 10.1016/j.nano.2009.05.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
103 Waikhom R, Taraphder A. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56:54-58. [PMID: 21572794 DOI: 10.4103/0019-5154.77554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
104 Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, Rossi Espagnet MC. Gadolinium-Based Contrast Agent-Related Toxicities. CNS Drugs 2018;32:229-40. [PMID: 29508245 DOI: 10.1007/s40263-018-0500-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
105 Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25. [PMID: 24111526 DOI: 10.1111/cei.12211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
106 Riser BL, Barnes JL, Varani J. Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal 2015;9:327-39. [PMID: 26698861 DOI: 10.1007/s12079-015-0309-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
107 Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008;34:199-220; ix. [PMID: 18329541 DOI: 10.1016/j.rdc.2007.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
108 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
109 Acar T, Kaya E, Yoruk MD, Duzenli N, Senturk RS, Can C, Ozturk L, Tomruk C, Uyanikgil Y, Rybicki FJ. Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents. Jpn J Radiol 2019;37:458-65. [PMID: 30929137 DOI: 10.1007/s11604-019-00835-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. Clin J Am Soc Nephrol 2010;5:964-71. [PMID: 20299369 DOI: 10.2215/CJN.00140110] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]